The second disease-modifying Alzheimer's treatment is here with more on the horizon, but is the healthcare ecosystem ready for their impact?
An analysis of Mounjaro's stand-out market performance and the shifts it signals in U.S. healthcare
The Inflation Reduction Act of 2022, and the complex chess game now in play for pharmaceutical manufacturers
From the U.S. Progress Point Editorial Board